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Abstract: Anilin actin binding protein (ANLN) and transducing-like enhancer protein 2 (TLE2) are 
associated with cancer patient survival and progression. The impact of their gene expression on 
progression-free survival (PFS) of patients with muscle invasive bladder cancer (MIBC) treated with 
radical cystectomy (RC) and subtype association has not yet been investigated. qRT-PCR was used 
to measure the transcript levels of ANLN and TLE2 in the Mannheim cohort, and validated in silico 
by The Cancer Genome Atlas (TCGA) cohort. Uni- and multivariate Cox regression analyses 
identified predictors for disease-specific survival (DSS) and overall survival (OS). In the Mannheim 
cohort, tumors with high ANLN expression were associated with lower OS and DSS, while high 
TLE2 expression was associated with a favorable OS. The TCGA cohort confirmed that high ANLN 
and low TLE2 expression was associated with shorter OS and disease-free survival (DFS). In both 
cohorts, multivariate analyses showed ANLN and TLE2 expression as independent outcome 
predictors. Furthermore, ANLN was more highly expressed in cell lines and patients with the basal 
subtype, while TLE2 expression was higher in cell lines and patients with the luminal subtype. 
ANLN and TLE2 are promising biomarkers for individualized bladder cancer therapy including 
cancer subclassification and informed MIBC prognosis. 
Keywords: muscle invasive bladder cancer; prognosis; biomarker; molecular subtype 
 
1. Introduction 
Bladder urothelial carcinoma (BLCA) is the most common urinary tumor worldwide with about 
386,000 new cases and nearly 150,200 deaths each year [1]. Non-muscle-invasive bladder cancers 
(NMIBC; 70%) are not immediately life threatening but often progress, while muscle-invasive 
bladder cancers (MIBC; 30%) are responsible for the most cases of metastases and death [2]. The 
current therapeutic standard for MIBC is radical cystectomy (RC) with perioperative platinum-based 
chemotherapy in selected cases [3]. The clinical management of MIBC is currently limited. First, 
potentially inadequate treatment decisions are informed by a limited clinicopathological staging 
system [4]. Therefore, mRNA-based molecular subtyping of MIBC, which shows target genes 
enriched in specific molecular subtypes, has emerged as a promising tool with the potential to stratify 
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patients for treatment [5]. Luminal and basal differentiated tumors are characterized by specific gene 
expression, such as Keratin 5 (KRT5) in the basal subtype and KRT20 in the luminal subtype [6]. 
Second, the onset of BLCA is a multi-factorial and multi-step formation process involving multiple 
genes [7,8]. Therefore, in-depth study of the molecular mechanisms of the genes closely related to the 
malignant progression of BLCA and therapeutic relevant targets will help to understand the 
regulatory mechanisms of key genes in the development and progression of BLCA. 
Anilin actin binding protein (ANLN) is located on chromosome 7q14.2 and encodes for a 1,125 
amino acid actin-binding protein that includes a conserved N-terminal actin (F-actin) and myosin 
binding region and a conserved C-terminal pH binding domain [9]. Previous studies found that 
ANLN expression levels were significantly up-regulated in a variety of tumor tissues, including 
breast, ovarian, colon, lung, and pancreatic cancers [10–15]. Furthermore, ANLN and its encoded 
protein are highly expressed in BLCA tissues, and their expression levels are positively correlated 
with the pathological grade and stage of BLCA [16]. However, the involved signaling pathways and 
the interacting molecular targets in the regulation of BLCA biological function are in discussion. 
Transducing-like enhancer protein 2 (TLE2), a member of the TLE gene family, is located on 
chromosome 19p13.3, and acts as a transcriptional corepressor [17]. Previous studies revealed that 
the molecular properties of the TLE2 protein point to a function in transcriptional regulation, 
involved in embryonic neuronal development in conjunction with Hairy/Enhancer of split (HES) 
proteins [17,18]. The TLE2 protein inhibits replication-and-transcription-activator-mediated 
transactivation and lytic reactivation of Kaposi’s sarcoma-associated herpesvirus [19]. The function 
of TLE2 in BLCA has not yet been investigated. 
In a previous study, ANLN expression was associated with Wnt/β-catenin signaling in gastric 
cancer [20]. Also, the Wnt/β-catenin pathway regulates gene expression via T-cell factor/lymphoid 
enhancer-binding factor 1 (TCF/LEF1) family, which is repressed by transcription factors for TLEs 
[21,22]. However, the association between ANLN and TLE2 was not elucidated yet. 
This study was the first to investigate the expression of TLE2 in human urothelial cell lines and 
MIBC samples in correlation with histopathology and survival data. The involved signaling 
pathways and the impact of ANLN and TLE2 on MIBC molecular subtypes were also evaluated. 
2. Results 
2.1. Patient Population and Survival Analysis 
Demographic and clinical-pathological data of the 60 patients with MIBC included in the 
Mannheim cohort are shown in Table 1. Median follow-up of the entire cohort was 15 months (range 
3–99 months) and the median follow-up of surviving patients was 38 months (range 9–99 months). 
In total, 26 patients (43.33%) suffered a relapse (local relapse n = 3, lymph nodes and/or distant 
metastases n = 15, unclear metastasis pattern n = 8). Of the 33 (55.00%) patients who died during the 
follow-up, 26 (43.33%) of them died due to BLCA. 
Table 1. Clinicopathological characteristics of patients and specimens of the Mannheim cohort. 
Clinicopathological Features n 
Age 
<70 23 
≥70 37 
Gender 
Male 47 
Female 13 
Grade 
Low 5 
High 55 
Stage 
T1 6 
T2 11 
T3 28 
T4 15 
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Lymph node metastasis 
Negative 37 
Positive 15 
2.2. ANLN and TLE2 as Risk Markers for Prognostic Prediction After RC 
In the Mannheim cohort, patients with high ANLN expression showed worse overall survival 
(OS) (n = 22 with low expression, n = 38 with high expression; median survival, 21 vs. 10 months, and 
p = 0.0010) and disease-specific survival (DSS) (n = 20 with low expression, n = 40 with high 
expression; median survival, 21 vs. 10 months, and p = 0.0060) after RC than patients with low 
expression (Figure 1a,b). Conversely, patients with high TLE2 expression displayed more favorable 
OS (n = 29 with high expression, n = 31 with low expression; median survival, 15 vs. 9 months, and p 
= 0.0236) and DSS (n = 29 with high expression, n = 31 with low expression; median survival, 31 vs. 
13 months, and p = 0.2083) than patients with low expression (Figure 1c,d). The gene expression levels 
were not normally distributed. 
 
Figure 1. Kaplan–Meier plots of overall- (OS) and disease-specific (DSS) survival associated with 
anilin actin binding protein (ANLN) and transducing-like enhancer protein 2 (TLE2) risk stratification in 
the Mannheim cohort. The group with high ANLN expression showed worse OS (a) and DSS (b) than 
the group with low expression. The group with high TLE2 expression displayed more favorable OS 
(c) and DSS (d) than the group with low expression. 
In the univariate and multivariate Cox regression analysis, ANLN (p = 0.0020 and p = 0.0390, 
respectively) and TLE2 (p = 0.0120 and p = 0.0020, respectively) expression were independent 
predictors. Furthermore, lymph node status was identified as an independent prognostic factor by 
both analyses (p = 0.0030 and p = 0.0240), as was lymphovascular invasion (LVI) (p = 0.0040) by only 
the univariate Cox regression analysis (Table 2). No significant correlation was observed between 
patient age, patient gender, or stage of tumor and ANLN and TLE2 expression. 
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Table 2. Univariate and multivariate Cox regression analysis of ANLN and TLE2 with 
clinicopathological features in the Mannheim cohort (HR = hazard ratio, CI = confidence interval, LVI 
= lymphovascular invasion, significant p Values are bold). 
Factor 
Univariate  Multivariate  
HR (95% CI) p Value HR (95% CI) p Value 
Diagnosis Age     
<70 vs. ≥70 0.584 (0.269–1.269) 0.174 − − 
Gender     
Male vs. Female 1.128 (0.405–3.140) 0.957 − − 
Stage     
T1/T2 vs. T3/4 0.168 (0.015–1.832) 0.128 − − 
LVI     
Negative vs. Positive 0.542 (0.359–0.819) 0.004 − − 
Lymph node Statues     
Negative vs. Positive 0.549 (0.371–0.813) 0.003 0.612 (0.399–0.938) 0.024 
ANLN     
Low vs. High 0.220 (0.084–0.575) 0.002 0.328 (0.114–0.945) 0.039 
TLE2     
Low vs. High 0.305 (0.121–0.769) 0.012 0.172 (0.057–0.519) 0.002 
In The Cancer Genome Atlas (TCGA) cohort, higher ANLN expression was associated with 
worse OS (n = 246 with low expression, n = 161 with high expression; median survival, 18.07 vs. 15.31 
months, and p = 0.0144) and disease-free survival (DFS) (n = 246 with low expression, n = 161 with 
high expression; median survival, 18.82 vs. 13.99 months, and p = 0.0045, Figure 2a,b). In contrast, 
higher TLE2 expression was associated with more favorable OS (n = 250 with low expression, n = 157 
with high expression; median survival, 16.69 vs. 18.99 months, and p = 0.0054) and DFS (n = 250 with 
low expression, n = 157 with high expression; median survival, 15.31 vs. 16.79 months, and p = 0.0094, 
Figure 2c,d). In the TCGA cohort, correlation between ANLN and TLE2 expression and stage showed 
that ANLN was significantly expressed in pT3 and pT4 (higher stages, median expression 9.95 vs. 
10.16, and p = 0.0109, Figure S1a), while TLE2 was dominantly expressed in pT2 (lower stage, median 
expression 9.88 vs. 9.73, and p = 0.0228, Figure S1b). Further analysis of the TCGA bladder cancer 
cohort according to clinical stage showed that lower ANLN (n = 77 with low expression, n = 41 with 
high expression; median survival, 23.43 vs. 19.66 months, and p = 0.0397) and TLE2 (n = 67 with low 
expression, n = 51 with high expression; median survival, 17.94 vs. 20.37 months, and p = 0.0100) 
expression in the pT2 subgroup could be attributed to a good and poor prognosis of OS, respectively 
(Figure 2e,f). Furthermore, the gene expression of ANLN and TLE2 was analyzed in subtypes of 
MIBC. Notably, in the TCGA cohort, ANLN expression in patients with MIBC and basal subtype was 
associated with worse OS (n = 61 with low expression, n = 81 with high expression; median survival, 
20.37 vs. 13.96 months, and p = 0.0467, Figure 2g) compared with the whole TCGA cohort. Higher 
TLE2 expression showed better OS in patients with MIBC and luminal subtype (n = 130 with high 
expression, n = 115 with low expression; median survival, 19.48 vs. 17.87 months, and p = 0.0181, 
Figure 2h) compared with the whole TCGA cohort. The gene expression levels were not normally 
distributed. 
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Figure 2. Kaplan–Meier plots of OS and disease-free survival (DFS) associated with ANLN and TLE2 
risk stratification in The Cancer Genome Atlas (TCGA) cohort. Higher ANLN expression showed 
worse OS (a) and DFS (b). Higher TLE2 expression showed more favorable OS (c) and DFS (d). In the 
T2 subgroup, low ANLN (e) and TLE2 (f) expression showed good and poor prognosis of OS, 
respectively. Higher ANLN expression showed worse OS in basal subtype (g) and higher TLE2 
showed better OS in luminal subtype (h). 
In the univariate Cox regression analysis of clinicopathological features, stage (p < 0.001), lymph 
node status (p < 0.001), ANLN (p = 0.0160), and TLE2 (p = 0.0060) expression were independent. 
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Furthermore, stage (p = 0.0060), ANLN (p = 0.0180), and TLE2 (p = 0.0400) were also independent 
prognostic factors in the multivariate Cox regression analysis (Table 3). 
Table 3. Univariate and multivariate Cox regression analysis of ANLN and TLE2 with 
clinicopathological features in the TCGA cohort (HR = hazard ratio, CI = confidence interval, 
significant p Values are bold). 
Factor 
Univariate  Multivariate  
HR (95% CI) p Value HR (95% CI) p Value 
Diagnosis Age     
<70 vs. ≥70 1.260 (0.931–1.705) 0.134 − − 
Gender     
Male vs. Female 1.257 (0.902–1.751) 0.177 − − 
Smoking Status     
No vs. Yes 1.335 (0.940–1.897) 0.106 − − 
Stage     
T2 vs. T3/4 1.950 (1.393–2.731) <0.001 1.646 (1.156–2.342) 0.006 
Lymph node Statues     
Negative vs. Positive 2.145 (1.596–2.883) <0.001 1.989 (1.461–2.707) <0.001 
ANLN     
Low vs. High 1.439 (1.070–1.934) 0.016 1.438 (1.064–1.943) 0.018 
TLE2     
Low vs. High 0.636 (0.460–0.880) 0.006 1.415 (1.015–1.973) 0.040 
2.3. Gene Expression Profiling of ANLN and TLE2 in Comparison with other Tumor Entities 
Bar plots compared the gene expression profiles across all 31 tumor samples and paired normal 
tissues from TCGA database. ANLN expression was confirmed to be up-regulated in the majority of 
tumor samples (26/31, 83.87%), while TLE2 was down-regulated in the majority of tumor samples 
(25/31, 80.64%). In BLCA tumor samples, ANLN expression was up-regulated (median expression 
16.72) compared to normal tissues (median expression 1.54; Figure S2a), while TLE2 expression was 
down-regulated (median expression 22.27) compared to normal tissues (median expression 60.99; 
Figure S2b). The dot-box plots with data normalized for log-scale showed that ANLN expression was 
significantly higher in BLCA tumor samples than normal tissues (median expression 4.15 vs. 1.34, 
and p < 0.001, Figure S2c). In contrast, TLE2 expression was significantly lower in BLCA samples than 
in normal tissues (median expression 4.54 vs. 5.95, and p < 0.001, Figure S2d). 
2.4. Association of Copy-number Alterations with ANLN and TLE2 Gene Expression 
Analysis of ANLN and TLE2 gene expression in association with copy-number alterations 
revealed a genetic alteration rate of 10% (41/407) for ANLN and 5% (21/407) for TLE2. Putative copy-
number alterations including deep/shallow deletion, diploid, gain, and amplification were acquired 
from GISTIC (Genomic Identification of Significant Targets in Cancer). The majority of copy-number 
alteration signatures for ANLN were gains and amplifications rather than deletions (number 173 vs. 
25, 42.51% vs. 6.14%, median expression 10.54 vs. 9.45, and p = 0.0002, Figure 3a). For TLE2, most 
samples showed deletion variations rather than amplifications (number 143 vs. 54, 35.14% vs. 13.27%, 
median expression 9.63 vs. 9.77, and p = 0.0394, Figure 3b). Significantly higher expression of ANLN 
was observed in the subgroup with gain compared to diploid (median expression 10.54 vs. 9.88, and 
p < 0.0001) and deletion (median expression 10.54 vs. 9.45, and p < 0.0001, Figure 3c). There were no 
significant differences in TLE2 expression in the subgroups with deletion compared to diploid 
(median expression 9.63 vs. 9.98, and p = 0.1458) or gain (median expression 9.63 vs. 9.73, and p = 
0.9190, Figure 3d). When gene expression levels were grouped into low and high expression, analysis 
revealed higher rates of amplification/gains in the subgroup with higher ANLN expression (n = 86, 
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56.90%) compared to lower ANLN expression (n = 77, 31.95%, Figure 3e). In contrast, amplification 
was only observed in 12.2% (n = 30) of the TLE2 low expression group and in 14.29% (n = 22) of the 
TLE2 high expression group (Figure 3f). Furthermore, higher rates of deletion were seen in the TLE2 
low expression subgroup than in the TLE2 high expression subgroup (n = 102, 41.46% vs. n = 40, 
25.97%). 
 
Figure 3. ANLN and TLE2 expression in association with copy-number alterations. ANLN showed 
6.14% of shallow/deep deletion, 51.35% of diploid, and 42.51% of gain/amplification (a). TLE2 showed 
35.14% of shallow/deep deletion, 51.60% of diploid and 13.27% of gain/amplification (b). Significant 
higher expression of ANLN was observed in the subgroup with gain than diploid (median expression 
10.54 vs. 9.88, and p < 0.0001) and deletion (median expression 10.54 vs. 9.45, and p < 0.0001) (c). No 
significant differences of TLE2 expression were found in the subgroups with deletion against diploid 
(median expression 9.63 vs. 9.98, and p = 0.1458) or gain (median expression 9.63 vs. 9.73, and p = 
0.9190) (d). The gene expression levels of ANLN and TLE2 were grouped into high and low 
expression. In the subgroup with lower ANLN expression, diploid (n = 143, 59.34%) was more 
frequently observed than gain (n = 77, 31.95%) and deletion (n = 21, 8.71%). The subgroup with higher 
ANLN expression is associated with a higher percentage of gain (n = 86, 56.90%) than diploid (n = 62, 
41.10%) and deletion (n = 3, 2.00%) (e). TLE2 was mainly expressed in the subgroup with deletion and 
diploid in TLE2 low expression (n = 102, 41.46% in deletion; n = 114, 46.34% in diploid) and TLE2 high 
expression (n = 40, 25.97% in deletion; n = 92, 59.74% in diploid). Gain was observed in only 12.2% (n 
= 30) in TLE2 low expression group and in 14.29% (n = 22) in the TLE2 high expression group (f). 
2.5. Correlation with Signaling Pathways and Therapeutic Targets in Bladder Cancer 
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The protein-protein interactions of ANLN and TLE2 were analyzed by Search Tool for Retrieval 
of Interacting Genes/Proteins (STRING, Figure S3). The number of counted gene sets and the false 
discovery rate for each Gene Ontology (GO) term are shown in Table S2. The interaction network 
based on curated databases and experimentally derived results showed that key molecules in 
signaling pathways were significantly correlated with ANLN and TLE2, including cell proliferation 
(false discovery rate, FDR = 1.99−10), Notch signaling (FDR = 2.38−9), Wnt signaling (FDR = 2.38−9), and 
hormone receptor (FDR = 3.16−8). The correlation with important therapeutic targets in BLCA, 
including epidermal growth factor receptor (EGFR) (p = 7.73−31 for ANLN and p = 1.78−14 for TLE2), Erb-B2 
receptor tyrosine kinase 2 (ERBB2) (p = 3.44−13 for ANLN and p = 1.96−43 for TLE2), fibroblast growth factor 
receptor 3 (FGFR3) (p = 6.52−9 for ANLN and p = 0.0016 for TLE2), and programmed death-ligand 1 (PD-
L1) (p = 2.89−18 for ANLN and p = 1.07−18 for TLE2) were found to be significantly correlated with ANLN 
and TLE2 based on TCGA data (Table 4). 
Table 4. Correlation of ANLN and TLE2 with key molecules in signaling pathways and therapeutic 
targets (correlation coefficient values above 0.4 and below −0.4 are bold). 
Correlated Gene 
ANLN TLE2 
Correlation 
Coefficient p Value 
Correlation 
Coefficient p Value 
Cell proliferation 
CDK1 0.594 3.98 × 10−40 −0.338 2.63 × 10−12 
RACGAP1 0.725 1.41 × 10−67 −0.451 9.46 × 10−22 
MKI67 0.711 7.56 × 10−64 −0.396 1.07 × 10−16 
FOXM1 0.688 2.98 × 10−58 −0.4 4.46 × 10−17 
Notch signaling 
NOTCH1 0.109 0.027294 −0.19 0.000115 
RBPJ −0.196 6.6 × 10−5 0.05 0.311468 
Wnt signaling 
TCF7 0.067 0.175097 0.006 0.89689 
TCF7L1 0.162 0.001066 −0.267 4.75 × 10−8 
TCF7L2 −0.186 0.000164 0.23 2.84 × 10−6 
LEF1 −0.101 0.041347 −0.026 0.596286 
CTNNB1 0.237 1.29 × 10−6 −0.276 1.6 × 10−8 
Hormone receptor 
signaling 
AR −0.185 0.000171 0.388 4.9 × 10−16 
ESR1 −0.003 0.944815 −0.048 0.332592 
ESR2 −0.191 0.00011 0.334 4.33 × 10−12 
FOXA1 −0.38 1.89 × 10−15 0.505 9.11 × 10−28 
GATA3 −0.403 2.33 × 10−17 0.65 2.80 × 10−50 
Therapeutic targets 
EGFR 0.53 7.73 × 10−31 −0.368 1.78 × 10−14 
ERBB2 −0.35 3.44 × 10−13 0.613 1.96 × 10−43 
FGFR3 −0.283 6.52 × 10−9 0.156 0.001575 
PIK3CA 0.426 2.19 × 10−19 −0.264 6.34 × 10−8 
CDK4 0.207 2.68 × 10−5 −0.267 4.69 × 10−8 
HRAS −0.023 0.648147 −0.183 0.000202 
PDCD1 0.0881 0.0754 −0.313 1.07 × 10−10 
PD-L1 0.414 2.89 × 10−18 −0.419 1.07 × 10−18 
CTLA4 0.0963 0.052 −0.363 3.71 × 10−14 
EZH2 0.446 2.51 × 10−21 −0.162 0.001009 
It is noteworthy that ANLN was positively correlated with cell proliferation markers including 
cyclin-dependent kinase 1 (CDK1) (ρ = 0.594, p = 3.98−40), Rac GTPase activating protein 1 (RACGAP1) (ρ = 
0.725, p = 1.41−67), marker of proliferation Ki-67 (MKI67) (ρ = 0.711, p = 7.56−64), and forkhead box M1 
(FOXM1) (ρ = 0.688, p = 2.98−58). In contrast, TLE2 was negatively correlated with cell proliferation 
molecules involving CDK1 (ρ = -0.338, p = 2.63−12), RACGAP1 (ρ = -0.451, p = 9.46−22), MKI67 (ρ = -0.396, 
p = 1.07−16), and FOXM1 (ρ = -0.400, p = 4.46−17). TLE2 was also correlated with molecules involved in 
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Wnt signaling including catenin beta 1 (CTNNB1) (ρ = -0.276, p = 1.6−8) and hormone receptors 
including forkhead box A1 (FOXA1) (ρ = 0.505, p = 9.11−28) and GATA binding protein 3 (GATA3) (ρ = 
0.65, p = 2.8−50; Table 4). Further, expression of RACGAP1, MKI67, FOXM1, CDK1, CTNNB1, and 
GATA3 were examined in the Mannheim cohort. This analysis showed that ANLN was significantly 
correlated with RACGAP1 (ρ = 0.455, p < 0.0001), FOXM1 (ρ = 0.549, p < 0.0001), MKI67 (ρ = 0.577, p < 
0.0001), and CDK1 (ρ = 0.763, p < 0.0001; Figure S4a–d). TLE2 was significantly correlated with GATA3 
(ρ = 0.409, p = 0.0012) and CTNNB1 (ρ = 0.363, p = 0.0070) (Figure S4e, f). Similar expression data was 
also detected in the urothelial cell lines (Figure S5a). 
2.6. Molecular Subtype Specificity of ANLN and TLE2 
In silico RNA-seq data from the Cancer Cell Line Encyclopedia showed ANLN and TLE2 
expression levels in TPM (transcripts per million) for 25 BLCA cell lines, with different molecular 
subtypes of each (basal, luminal, and mixed; Figure S5b). Cell lines that were classified as basal 
subtypes, including UMUC3 and SCaBER, showed slightly higher expression of ANLN, while TLE2 
dominantly expressed in cell lines classified as luminal subtypes, e.g., RT112 and RT4. qPCR based 
on SYBR Green showed relative expression of ANLN and TLE2 in five malignant urothelial cell lines 
(RT4, RT112, UMUC3, T24, and ScaBER), which correspond with the RNA-seq data (Figure S5a). 
Similarly, in patients with BLCA (TCGA, Provisional), expression of ANLN was higher in the basal 
than in the luminal subtypes (median expression 10.93; range 6.1–13.01 vs. median expression 9.64; 
range 4.87–12.25, p < 0.0001, Figure S5c) according to the mRNA clustering. In contrast, TLE2 showed 
an opposite trend with a higher expression in luminal than basal subtypes (median expression 10.41; 
range 5.04–12.55 vs. median expression 7.41, range 1.79–12.25, p < 0.0001, Figure S5d). In addition, the 
basal subtype marker KRT5 and the luminal subtype marker KRT20 were analyzed in the Mannheim 
cohort. KRT5 was significantly correlated with ANLN (ρ = 0.278, p = 0.042; Figure S6a), and KRT20 
was significantly correlated with TLE2 (ρ = 0.296, p = 0.026; Figure S6b). The expression of ANLN and 
TLE2 were also analyzed in the high KRT5 and the high KRT20 expression group, which were 
classified based on median expression of KRT5 and KRT20. It was observed that ANLN expression 
was higher in the high KRT5 group than in the high KRT20 group (p = 0.1119, Figure S6c), and TLE2 
expression was higher in the high KRT20 group than in the high KRT5 group (p = 0.1413, Figure S6d). 
3. Discussion 
This study aimed to retrospectively evaluate the prognostic and clinical impact of ANLN and 
TLE2 gene expression and to validate these results in published datasets. In order to evaluate the 
translational benefit, gene expression was compared with molecular subtypes, targets, and relevant 
clinicopathologic parameters in multivariable analyses. Higher ANLN transcript levels were found 
to be associated with worse OS and DSS in the Mannheim cohort, which corresponds with results 
from previous studies of BLCA and upper urinary tract urothelial carcinoma [23]. Together, these 
results indicate that ANLN, in addition to lymph node status, may be an independent predictor for 
progression-free survival (PFS), and superior to the use of T stage and LVI as predictors. As a key 
regulator of cytokinesis, it is not surprising that ANLN might play a critical role in carcinogenesis 
[24]. Previous research has established that knockdown of ANLN could significantly inhibit the 
proliferation of bladder cancer both in vitro and in vivo. Furthermore, knockdown of ANLN strongly 
suppressed the migration and invasion ability of J82 and 5637 bladder cancer cell lines [16]. 
Additionally, in upper urinary tract urothelial carcinoma, overexpression of ANLN in the nucleus is 
a poor prognostic factor, which was confirmed by data on protein levels, while low expression of 
ANLN in the cytoplasm is a poor prognosis maker [23]. 
In contrast to ANLN, TLE2 was found to be dominantly expressed in patients with lower stages 
of BLCA. Patients with higher TLE2 expression had a more favorable OS and DFS, both in the whole-
stage group and in the T2 subgroup. These results, together with univariate and multivariate Cox 
regression analysis of the Mannheim and the TCGA cohort, suggest that TLE2 could serve as an 
independent risk factor for prognostic prediction of patients with BLCA. The most recent research 
about TLE2 showed an inhibition of replication and transcription in Kaposi’s sarcoma-associated 
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herpesvirus [19]. To our knowledge, there is only very limited data about the role of TLE2 in cancer 
and no data specific to BLCA. Therefore, our findings are the first describing the role of TLE2 in 
BLCA. In adition, the Kaplan–Meier curves of ANLN and TLE2 with OS and DSS showed separation 
at earlier time points, but convergence at later time points, between the high and low expression 
group in the TCGA cohort. It indicated that the predictive capabilities of ANLN and TLE2 expression 
might be stronger at earlier time points after RC. 
In our study, ANLN expression was strongly correlated with cell proliferation markers including 
CDK1, RACGAP1, MKI67, and FOXM1. In urothelial carcinoma cell lines, these genes showed a 
consistently strong positive correlation with the expression of ANLN, which is highly expressed in 
ScaBER cells and expressed in low amounts in RT4 cells. In our patient cohort, we also found a strong 
correlation of ANLN with RACGAP1, MKI67, and CDK1. These results indicate that ANLN could have 
a crucial role in tumor proliferation of MIBC. It is already known that the proliferation markers MKI67 
and RACGAP1 have a significant importance in BLCA [25,26]. Previous research showed that mRNA 
expression of MKI67 is significantly correlated and associated with stage and grade in NMIBC [27]. 
Furthermore, the expression of RACGAP1 correlated significantly with the tumor stage in BLCA after 
RC, and RACGAP1 was strongly expressed in the early stages of NMIBC patient samples [28]. 
Additionally, FOXM1 has been shown to be overexpressed on the mRNA and protein levels in 
bladder cancer cells, and plays an important role in cisplatin resistance, outcome prediction, and risk 
stratification of patients with BLCA [29]. 
In this study, TLE2 expression correlated with several Wnt pathway components, such as β-
catenin (CTNNB1), TCF7, and LEF1 in the TCGA cohort. By analyzing the expression in the 
Mannheim cohort, it was also found that TLE2 was significantly correlated with CTNNB1. In 
addition, CTNNB1 is highly expressed in RT4 cells and expressed in lower amounts in ScaBER cells, 
which is similar to the expression pattern of TLE2. The activation of the Wnt/β-catenin signaling 
pathway plays an important role in tumorigenesis and development of various cancers including 
BLCA [30–32]. Gain-of-function mutations in CTNNB1 are detected in numerous human cancers [33–
35]; therefore, it is necessary to explore the role of Wnt/β-catenin regulated genes in BLCA. Previous 
research has shown that TLE2 was significantly suppressed and the level of β-catenin protein was 
increased in esophageal tumor cells, both of which were modulated by NDRG1 overexpression [36]. 
Interestingly, ANLN positively correlates with CTNNB1, while TLE2 correlates inversely with 
CTNNB1, which was also observed in the Mannheim cohort. Although there is no direct correlation 
between ANLN and TLE2 in both cohorts, the involvement of ANLN and TLE2 underlying the Wnt/β-
catenin signaling pathway was preliminarily revealed by our study. 
To reveal more details of ANLN and TLE2 expression in bladder cancer, the RNA-seq data of 
transcripts based on TCGA cohort were analyzed. Interestingly, the splice variants of ANLN and 
TLE2 showed different expression levels, with ANLN-201 (ENST00000265748.6), ANLN-202 
(ENST00000396068.6), ANLN-210 (ENST00000457743.1), ANLN-212 (ENST00000491782.1), TLE2-201 
(ENST00000262953.10), TLE2-202 (ENST00000426948.6), TLE2-204 (ENST00000455444.6), and TLE2-
215 (ENST00000590101.5) highly expressed compared with other transcripts. These findings indicate 
that differential expression patterns of ANLN and TLE2 splice variants might potentially have a 
practical usefulness, which needs further investigations. 
Our study demonstrates that ANLN and TLE2 show a distinct subtype-specific overexpression 
in BLCA cell lines. ANLN showed overexpression in basal-like urothelial carcinoma cell lines and 
patients, while TLE2 showed significantly higher expression in luminal-like urothelial carcinoma cell 
lines and patients. Interestingly, for patients with MIBC in the whole TCGA cohort, ANLN and TLE2 
harbored similar prognostic values for basal and luminal subtypes, respectively. Molecular 
classification has emerged as a promising research tool beyond histopathology to stratify cancer 
patients for personalized medicine [37]. Recent years have witnessed increasing interest and research 
into the molecular basis of bladder cancer [6]. Several studies subclassified both MIBC and NMIBC 
through RNA-seq-based data and identified distinct molecular subtypes that correlated well with 
outcome and therapy response [5,38,39]. MIBC molecular subtypes, which are broadly grouped into 
basal and luminal subtypes, showed similarities to the molecular phenotypes of breast cancer [40]. It 
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is believed that epithelial-to-mesenchymal transition (EMT) is a critical step in the progression of 
breast cancer, particularly the basal-like one [41]. The basal and EMT/claudin-low markers were 
highly expressed in the same subtype of patients with BLCA based on the TCGA database [42]. Due 
to the significant association with basal subtype of BLCA, it is suggested that ANLN could play a 
potential role in EMT in BLCA. Also, KRT5 is highly upregulated in basal and KRT20 in luminal 
subtype in BLCA [6]. qPCR-based molecular subtyping of BLCA by KRT5 and KRT20 mRNA 
expression is a method associated with the survival of patients with MIBC [43]. It is confirmed that 
KRT5 and KRT20 showed significant association with ANLN and TLE2 in the Mannheim cohort. The 
differences of ANLN and TLE2 expression were not significant in the high KRT5 and KRT20 group 
maybe due the fact that only KRT5 and KRT20 were used for subtype association. 
Until recently, effective targets following platinum-based chemotherapy were limited for 
patients with advanced urothelial carcinoma. The most promising option is immunotherapy with 
programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors, 
coupled with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies [44,45]. 
Apart from differences in expression thresholds for defining PD-L1 positivity, the validated 
biomarkers for optimal patient selection are still unrevealed [46]. In our study, expression of ANLN 
and TLE2 correlate with the therapeutic targets for bladder cancer as indicated in existing research 
and clinical trials. Notably, ANLN was positively and TLE2 was negatively correlated with PD-L1 in 
the TCGA cohort. TLE2 also showed a negative correlation with PD-1 and the key immunoregulator 
CTLA-4. These results suggest that ANLN and TLE2 could serve as potential biomarkers for response 
to immunotherapy and precise therapeutic management of MIBC. 
4. Materials and Methods 
4.1. Patients and Tissue Samples 
This study retrospectively enrolled sixty patients who received RC at the Department of Urology 
and Urosurgery of the University Medical Centre Mannheim between 2008 and 2011 and who had a 
histological diagnosis of MIBC (n = 47, 78% male, median age: 72 years, range: 41–87 years; n = 13, 
22% females, median age: 74 years, and range: 71–86 years; Mannheim cohort). All patients were 
treated with RC and bilateral lymphadenectomy without preoperative or adjuvant chemotherapy or 
radiotherapy. With the help of the clinic’s internal documentation program, the following parameters 
were collected after examination of the pathology findings: sex, age, T-stage, N-stage, M-stage, 
grading, lymphovascular invasion (LVI), blood vessel invasion (VI), simultaneous carcinoma in situ 
(CIS), multifocality, and soft tissue positive surgical margin. 
Formalin fixed paraffin embedded (FFPE) tumor tissue samples were evaluated for pathological 
stage according to the 2017 TNM classification from the Union for International Cancer Control 
(UICC) [47]. Tumors were graded using the 2017 WHO/ISUP classification [48] (Table 1). Studies 
involving human participants were approved by the ethical board of University Medical Centre 
Mannheim (2015-549-MA) and performed in accordance with relevant guidelines and regulations. 
The Cancer Genome Atlas cohort (TCGA, Provisional) contained RNA sequencing data of 407 
patients with MIBC and complete clinicopathological data and follow-up data. 
4.2. Database 
Expression data of 25 human bladder cancer cell lines were collected from Cancer Cell Line 
Encyclopedia (Novartis/Broad, Nature 2012), including 20 bladder urothelial cell carcinomas, one 
bladder squamous cell carcinoma, and four bladder carcinoma cell lines from unknown primaries. 
Expression of ANLN and TLE2 were analyzed by Expression Atlas (https://www.ebi.ac.uk/gxa/home) 
and normalized by transcripts per million (TPM). Expression data of 9736 tumor samples and 8,587 
normal samples across 31 types of tissues were collected from TCGA (https://tcga-
data.nci.nih.gov/tcga/) and the Genotype-Tissue Expression (GTEx) projects (https://gtexportal.org/) 
and analyzed by cBioPortal (http://www.cbioportal.org/) and Gene Expression Profiling Interactive 
Analysis (GEPIA, http://gepia.cancer-pku.cn) [49]. The height of a bar in the resulting bar plots 
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represents the median expression tumor types or normal tissue. Each dot represents the expression 
of ANLN and TLE2 in samples in the dot-box plots. The protein-protein interactions were analyzed 
by STRING (https://string-db.org/). GO enrichment analysis and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways were analyzed by Enrichr (http://amp.pharm.mssm.edu/Enrichr/) [50]. 
Expression of transcripts and exons was analyzed by Xena (https://xena.ucsc.edu/). 
4.3. Cell Lines 
Six different cell lines were used in this study, including one normal human urothelium cell line 
(UROtsa), two basal-like urothelial carcinoma cell lines (ScaBER and UMUC3), two luminal-like 
urothelial carcinoma cell lines (RT112 and RT4), and one mixed-type urothelial carcinoma cell line 
(T24). UROtsa cells were cultured in Roswell Park Memorial Institute medium (RPMI) with 5% fetal 
bovine serum (FBS). RT112, RT4, ScaBER, and UMUC3 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% FBS. T24 cells were cultured in McCoy’s 5A medium 
containing 10% FBS. UMUC3, ScaBER, RT112 and T24 cells were obtained from the European 
Collection of Authenticated Cell Cultures (ECACC), RT4 from the American Type Culture Collection 
(ATCC), and UROtsa cells from a collaborator. All cells were incubated at 37 °C in an atmosphere of 
5% CO2, per manufacturer instructions. Before starting the experiment, all cell lines were 
authenticated by Multiplexion (Heidelberg, Germany). 
4.4. RNA Extraction and qRT-PCR 
The total RNA of all cell lines was isolated using the RNeasy Mini kits (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions using a high salt buffer content and binding 
of RNA to a silica membrane. After washing steps, contaminants were removed and then RNA was 
eluted in RNase-free water. For FFPE tissues, RNA was extracted and enriched using the magnetic-
bead-based XTRAKT FFPE Kit (Stratifyer, Cologne, Germany) according to the instructions of 
manufacturer [28]. Next, reverse transcription was performed for cell samples using the M-MLV 
Reverse Transcriptase kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), and, for FFPE 
samples, using the Superscript III® reverse transcriptase kit (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) with sequence-specific primers. qPCR was used to measure relative mRNA 
expression with TaqMan Fast advanced Master Mix (Invitrogen, Thermo Fisher Scientific, Waltham, 
MA, USA). Experiments were performed on a StepOnePlus (Applied Biosystems, Darmstadt, 
Germany) with 20 s at 95 °C, followed by 40 cycles of 3 s at 95 °C, and 30 s at 60 °C. β-Glucuronidase 
(GUS) and Calmodulin2 (Calm2) were measured as reference genes [51,52]. The relative mRNA 
expression level was normalized to reference genes and determined using the 2−ΔΔCT method for cell 
culture samples and the 40-∆CT for FFPE samples, as previously described [53]. All primers and 
probes used in this study are shown in Supplementary Table S1. 
4.5. Statistical Analysis 
Statistical analyses were performed with SPSS 20.0 (IBM, Chicago, IL, USA) and GraphPad 
Prism 6.0 (GraphPad Software, La Jolla, CA, USA). A Kolmogorov–Smirnov (K-S) test was used to 
determine whether the data were normally distributed. Student’s t-tests were used to compare 
between groups of normally distributed numerical data, while Mann–Whitney U and Kruskal–Wallis 
tests were used to compare the non-normally distributed numerical data. Linear regression was used 
to determine the efficiency of amplification. Spearman tests were used to test the correlation between 
different gene expressions. The cut-off values (2−ΔΔCT value) of the high (≥0.047466) and low 
(<0.047466) ANLN expression groups, as well as the high (≥0.616383) and low (<0.616383) TLE2 
expression groups were determined by receiver operating characteristic (ROC) curve analysis in the 
Mannheim cohort [54]. Similarly, in the TCGA cohort, the cut-off value (log2 value) of high (≥10.695 
in the whole group and ≥10.8268 in the basal subgroup) and low (<10.695 in the whole group and 
<10.8268 in the basal subgroup) ANLN expression group, as well as high (≥4.97 in the whole group 
and ≥10.3605 in the luminal subgroup) and low (<4.97 in the whole group and <10.3605 in the luminal 
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subgroup) TLE2 expression group was determined by ROC curve analysis. The Cox regression model 
was used for univariate and multivariate analysis to calculate hazard ratio (HR). Survival rates of 
patients were calculated by the Kaplan–Meier method, and comparison was made by the log-rank 
test. In all cases, p < 0.05 was considered statistically significant. 
5. Conclusions 
This study provides in silico and in vitro evidence supporting the prognostic potential of ANLN 
and TLE2 for patients with MIBC. These results indicate that developing ANLN and TLE2 as new 
biomarkers will help to further optimize personalized therapy for these patients. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Primers and 
probes used in this study, Table S2: GO enrichment analysis by Enrichr indicated the significant GO terms for 
ANLN and TLE2 including biological process, molecular function, cellular component, and KEGG pathways, 
Figure S1: Correlation between ANLN and TLE2 expression and stage from the TCGA bladder cancer cohort 
(TCGA, Provisional) showed that ANLN was significantly expressed in higher T3-4 stages (median expression 
9.95 vs. 10.16, p = 0.0109) (a), while TLE2 was dominantly expressed in lower T2 stage (median expression 9.88 
vs. 9.73, p = 0.0228) (b), Figure S2: Expression of ANLN and TLE2 in BLCA tumor samples compared with normal 
tissues. ANLN expression was up-regulated (median expression 16.72) in tumors compared with normal tissues 
(median expression 1.54) based on TCGA data (a). TLE2 expression was down-regulated in tumors (median 
expression 22.27) compared with normal tissues (median expression 60.99) based on TCGA data (b). ANLN 
expression was significantly higher in BLCA tumor samples than normal tissues (median expression 4.15 vs. 
1.34, p < 0.001) based on TCGA and GTEx projects (c), while TLE2 expression was significantly lower in in BLCA 
tumor samples than normal tissues (median expression 4.54 vs. 5.95, p < 0.001) based on TCGA and GTEx projects 
(d), Figure S3: Protein-protein interactions predicted by STRING showed the interaction network of ANLN (a) 
and TLE2 (b) based on curated databases and experimental determination. Figure S4: Correlation of selected 
genes in the Mannheim cohort. ANLN was significantly correlated with RACGAP1 (a), FOXM1 (b), MKI67 (c), 
and CDK1 (d). TLE2 was significantly correlated with GATA3 (e) and CTNNB1 (f), Figure S5: qPCR showed 
relative expression of ANLN and TLE2 in five malignant urothelial cell lines (RT4, RT112, UMUC3, T24, and 
ScaBER) (a). In silico RNA-seq data from the Cancer Cell Line Encyclopedia showed expression level in TPM 
(transcripts per million) for ANLN and TLE2 in 25 BLCA cell lines with different molecular subtypes of each (b). 
Expression of ANLN was higher in basal than luminal subtype (median expression 10.93 with range of 6.1 to 
13.01 vs. median expression 9.64 with range of 4.87 to 12.25, p < 0.0001) in patients with BLCA (c). TLE2 
expression was higher in luminal than basal subtype (median expression 10.41 with range of 5.04 to 12.55 vs. 
median expression 7.41 with range of 1.79 to 12.25, p < 0.0001) (d), Figure S6: Correlation of KRT5 and ANLN (a) 
and KRT20 and TLE2 (b) in the Mannheim cohort. ANLN expression was higher in the high KRT5 group than in 
the high KRT20 group (p = 0.1119, (c), and TLE2 expression was higher in the high KRT20 group than in the high 
KRT5 group (p = 0.1413, d). 
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